Nomathemba Chandiwana

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

François Venter, Michelle Moorhouse, Simiso Sokhela et al. · New England Journal of Medicine · 2019 · 717 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

François Venter, Simiso Sokhela, Bryony Simmons et al. · The Lancet HIV · 2020 · 260 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Bronwyn Bosch, Godspower Akpomiemie, Nomathemba Chandiwana et al. · Clinical Infectious Diseases · 2022 · 57 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa

Nomathemba Chandiwana, Shobna Sawry, Matthew Chersich et al. · Medicine · 2018 · 36 citations · Full text

Public Health, Child Health, Pediatrics +17

Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens

Simiso Sokhela, François Venter, Bronwyn Bosch et al. · Open Forum Infectious Diseases · 2024 · 35 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16